Oncolytics Biotech (ONCY)

3.40 -0.07  -2.02%  May 31, 5:21PM Go Pro
Watch this stock
View Full Chart ONCY Price Chart

Key Stats

Market Cap 259.83M
Revenue Growth
Profit Margin
Earnings Yield -11.76%
Dividend Yield 0.00%
Earnings Per Share TTM -0.40
PE Ratio
Price / Sales Ratio
52 Week High 6.47
52 Week Low 3.15
Beta 1.570
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

May 30 Hyper-Novel Investments For Targeting Cancer
May 29 Health Care Sector Wrap Fox Business
May 15 Oncolytics Biotech® Inc. to Present at Bank of America Merrill Lynch 2012 Heath Care ...
May 10 $ONCY forms bullish "Continuation Wedge" chart pattern. http://stks.co/3mV6 by RecogniaEvents
May 10 Oncolytics Biotech® Inc. Announces First Quarter 2012 Results
May 03 Oncolytics Biotech® Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomiz...
Apr 04 Media Advisory - Oncolytics Biotech® Inc. to Present at 11th Annual Needham Healthcar...
Apr 02 Oncolytics Biotech Completes Enrollment in First Stage of Phase III Study in Head and...
Apr 02 Oncolytics Biotech (ONCY) Completes Enrollment in REOLYSIN w/ Aclitaxel and Carboplat...
Apr 02 Oncolytics Biotech® Inc. Completes Enrollment in First Stage of Phase III Study in He...
Mar 23 $ONCY Just got 500 shares at $4.17 and plan to buy more depending on what happens in a few days from now. Hope that phase 3 trial succeeds. by Foghornreturns
Mar 21 $ONCY I went out to buy it at 3.91 and it jumped to $4.20 right before my very eyes. I bet if I buy it "NOW" it will go down to $2.73. by Foghornreturns
Feb 23 $THLD bandwagon = $LXRX,$GNOM, $OREX, $SGMO, $ENMD, $SVNT, $NSPH (thin), $SQNM, $ONCY by teevee
Feb 17 Anyone trading $oncy by pjeffry000

Profile

Exchange: NASDAQCM       Sector: Healthcare       Industry: Biotechnology

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that focuses on the discovery and development of pharmaceutical products for the treatment of human cancers. The Company’s product, Reolysin, harnesses the oncolytic capabilities of naturally-occurring reovirus, which has been shown to replicate specifically in cells with an activated Ras pathway. Ras pathway mutations are found in approximately two thirds of all tumours, including most metastatic disease, which makes Reolysin a potential therapeutic for a variety of cancer types.

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Oncolytics Biotech is down 46.71% over the last year vs S&P 500 Total Return up 0.88%, BioLineRx up 0.00%, and Achillion Pharmaceuticals down 4.21%.

  • ONCY Total Returns
  • ^SPXTR Total Returns
  • BLRX Total Returns
  • ACHN Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Get Quote for

Pro Strategies Featuring ONCY

Did Oncolytics Biotech make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

ONCY Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
ONCY 3.40 -0.07 -2.02% 265.18M
ONB 11.59 +0.03 +0.26% 1.092B
OMX 4.88 +0.10 +2.09% 413.80M
OMPI 12.39 -0.20 -1.59% 235.31M
OMN 7.19 +0.07 +0.98% 326.02M
OMI 28.46 +0.30 +1.07% 1.790B
OMG 18.21 -0.49 -2.62% 604.57M
SHPGY 84.41 -1.70 -1.97% 16.15B
SHP 6.43 +0.05 +0.78% 119.11M
SHOR 4.19 +0.17 +4.23% 193.64M
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close